Krilogy Financial LLC Raises Stock Holdings in AbbVie Inc. $ABBV

Krilogy Financial LLC lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 41.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,719 shares of the company’s stock after buying an additional 4,919 shares during the quarter. Krilogy Financial LLC’s holdings in AbbVie were worth $3,624,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its position in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC lifted its holdings in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Cornerstone Wealth Group LLC boosted its position in AbbVie by 2.4% during the 2nd quarter. Cornerstone Wealth Group LLC now owns 67,304 shares of the company’s stock worth $12,493,000 after acquiring an additional 1,571 shares during the period. Alpine Woods Capital Investors LLC grew its position in AbbVie by 1.8% during the second quarter. Alpine Woods Capital Investors LLC now owns 35,403 shares of the company’s stock valued at $6,572,000 after purchasing an additional 642 shares in the last quarter. Finally, Jag Capital Management LLC grew its holdings in shares of AbbVie by 21.0% during the 2nd quarter. Jag Capital Management LLC now owns 1,256 shares of the company’s stock valued at $233,000 after acquiring an additional 218 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Scotiabank initiated coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. BMO Capital Markets restated an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research note on Thursday, January 15th. Berenberg Bank set a $275.00 price target on AbbVie in a report on Tuesday, January 20th. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $251.00.

AbbVie Price Performance

ABBV opened at $222.32 on Wednesday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The business’s 50-day moving average price is $223.67 and its two-hundred day moving average price is $220.29. The company has a market capitalization of $392.93 billion, a price-to-earnings ratio of 94.20, a P/E/G ratio of 0.78 and a beta of 0.35.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business’s revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.